Spots Global Cancer Trial Database for cd19 positive
Every month we try and update this database with for cd19 positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. | NCT04037566 | Leukemia Lympho... Leukemia Lympho... Lymphoma, B-Cel... CD19 Positive | XYF19 CAR-T cel... Cyclophosphamid... Fludarabine | 18 Years - 55 Years | Xijing Hospital | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | NCT03579927 | CD19 Positive Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Refractory B-Ce... Refractory Diff... Refractory Foll... | Autologous Hema... Carmustine Cytarabine Etoposide Filgrastim Melphalan Rituximab Umbilical Cord ... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia | NCT05563545 | Acute Lymphobla... | CAR-NK-CD19 Cel... | 3 Years - | Shanghai Simnova Biotechnology Co.,Ltd. | |
| CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | NCT03275493 | Acute Lymphobla... CD19 Positive Relapse Refractory | CD19 CAR-T cell... CD19 CAR-T cell... | 6 Years - 65 Years | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | NCT03605589 | Leukemia, B-cel... Lymphoma, B-Cel... | Blinatumomab Pembrolizumab | 1 Year - 40 Years | Children's Hospital Medical Center, Cincinnati | |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | NCT03512405 | CD19 Positive Philadelphia Ch... Recurrent Acute... Refractory Acut... | Blinatumomab Laboratory Biom... Pembrolizumab | 18 Years - | City of Hope Medical Center | |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | NCT03605589 | Leukemia, B-cel... Lymphoma, B-Cel... | Blinatumomab Pembrolizumab | 1 Year - 40 Years | Children's Hospital Medical Center, Cincinnati | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | NCT03233854 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... NKTR-255 | 18 Years - | Stanford University | |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | NCT05410041 | Acute Lymphocyt... Chronic Lymphoc... Non Hodgkin Lym... | CAR-NK-CD19 Cel... | 18 Years - | Beijing Boren Hospital | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
